The Claim

Among Medicare Advantage beneficiaries with type 2 diabetes, initiation of glucagon-like peptide-1 receptor agonists is associated with pharmacy costs that are 6% to 9% higher than initiation of sodium-glucose cotransporter-2 inhibitors, across all subgroups (overall, ASCVD, or obesity), and this difference is primarily driven by drug pricing variations.

Source: Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
67score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

Among Medicare Advantage patients with type 2 diabetes, those who start GLP-1 RA medications pay 6% to 9% more in pharmacy costs than those who start SGLT2i medications, regardless of whether they have heart disease or obesity, because the GLP-1 RA drugs are priced higher.

See the scientific wording

In Medicare Advantage beneficiaries with type 2 diabetes, pharmacy costs are consistently 6% to 9% higher for those initiating glucagon-like peptide-1 receptor agonists (GLP-1 RA) compared to those initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i), regardless of subgroup (overall, ASCVD, or obesity), indicating that drug pricing differences are the primary driver of total cost variation.

Why this might work

GLP-1 receptor agonists cost more to produce and sell than SGLT2 inhibitors, so when patients start taking them, their pharmacy bills go up by 6% to 9% because the drugs themselves are priced higher, and this difference is not offset by changes in hospital visits or other medical use.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.

    The study found that for older adults with diabetes, GLP-1 RA pills cost 6% to 9% more than SGLT2i pills every year, no matter if they had heart disease or obesity — and that’s the main reason their total medical bills are higher. Hospital visits didn’t change, so the price difference is all about the drug cost.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.